Stem Cells http://www.peprotech.com/
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bennett, C. L.
Right arrow Articles by Gulati, S. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bennett, C. L.
Right arrow Articles by Gulati, S. C.

Stem Cells, Vol 13, 414-420, Copyright © 1995 by AlphaMed Press

SPECIAL SECTION

Granulocyte-macrophage colony-stimulating factor as adjunct therapy in relapsed lymphoid malignancy: implications for economic analyses of phase III clinical trials

CL Bennett, SL George, JM Vose, JJ Nemunaitis, JL Armitage, JO Armitage, NC Gorin and SC Gulati
Lakeside Veterans Affairs Hospital, Chicago, Illinois, USA.

With the increasing concern over the high cost of health care, policy makers have incorporated economic analyses into phase III clinical trials as the randomized clinical trials can provide important information on the efficacy and potential cost-effectiveness of new pharmaceutical agents. Economic analyses of single-hospital experience during phase III trials of granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct therapy for high dose chemotherapy with autologous stem cell support found significant shortening of neutropenia with GM-CSF at each hospital, but shortened hospitalization (and lower costs) at only two of three hospitals. In this study, we added data from three additional hospitals and found that the 103 patients who received GM-CSF had, on average, 5.7 days shorter durations of severe neutropenia than the 95 patients who received placebo (p < 0.0001) and 3.4 days shorter in hospitalization (p = 0.06). However, the duration of hospitalization, the primary determinant of health care costs, was shorter for GM-CSF patients in only four of the six centers and the duration of hospitalization of placebo patients was shorter at the other two centers. Careful analyses must be carried out when phase III clinical trial results are used to derive estimates of cost-effectiveness of new pharmaceutical agents. The interpretation of economic analyses of phase III clinical trials raises issues related to the perspective of the investigators, study design, collection of data on resource utilization, learning curve effects and generalizability of the results to other settings.


This article has been cited by other articles:


Home page
 JCOHome page
A. Dekker, S. Bulley, J. Beyene, L. L. Dupuis, J. J. Doyle, and L. Sung
Meta-Analysis of Randomized Controlled Trials of Prophylactic Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor After Autologous and Allogeneic Stem Cell Transplantation
J. Clin. Oncol., November 20, 2006; 24(33): 5207 - 5215.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
M. Friedberg, B. Saffran, T. J. Stinson, W. Nelson, and C. L. Bennett
Evaluation of Conflict of Interest in Economic Analyses of New Drugs Used in Oncology
JAMA, October 20, 1999; 282(15): 1453 - 1457.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
J. C.L. Schuh and P. J. Morrissey
Development of a Recombinant Growth Factor and Fusion Protein: Lessons from GM-CSF
Toxicol Pathol, January 1, 1999; 27(1): 72 - 77.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
STEM CELLS THE ONCOLOGIST CME ALPHAMED PRESS JOURNALS

Copyright © 1995 by AlphaMed Press.